Targets › CSF2RA
1 program from 1 company in 24 trials: 19 Phase 2, 5 Phase 1; Neurology, Oncology; next expected readout Apr 2028.
Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells. (UniProt, P15509)
Open in Phaseline: the race on CSF2RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Y-mAbs Therapeutics | Sargramostim Granulocyte-macrophage colony-stimulating factor receptor agonist | CSF2RA, CSF2RB | Phase 2 | Neuroblastoma; Bilateral Breast Carcinoma; Neuroblastoma Recurrent; Alzheimer Disease … | Apr 2028 |
Neuroblastoma (2) Bilateral Breast Carcinoma (1) Neuroblastoma Recurrent (1) Alzheimer Disease (1) Solid Cancer (1) Transplant-Related Hematologic Malignancy (1) Cervical Cancer (1) Advanced Melanoma (1) Anatomic Stage IV Breast Cancer AJCC v8 (1) Oncology (1) Recurrent Osteosarcoma (1) Ganglioneuroblastoma, Nodular (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.